ArticleJournal of the International AIDS Society2026
Persistence on Oral HIV Pre-Exposure Prophylaxis Among Key Populations at a Centre in Buenos Aires: A Survival Analysis of a Real-World Cohort.
Article in Journal of the International AIDS Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Latin America and the Caribbean: Socioeconomic Realities and Implications for Health and HIV Responses.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough HIV pre-exposure prophylaxis (PrEP) has been rapidly scaled up in Argentina to reach key populations with high HIV burden, evidence on real-world persistence is lacking. Understanding who remains engaged in care, and why others discontinue, is essential to ensure the effectiveness of PrEP. This study evaluated oral PrEP persistence and identified demographic and behavioural factors associated with discontinuation in a cohort of individuals initiating PrEP in Buenos Aires.
methodsWe performed a retrospective cohort study including all users initiating daily or event-driven oral PrEP at our centre between September 2021 and July 2025. The cohort consisted of transgender women (TGW), men who have sex with men (MSM) and cisgender women engaged in sex work (cSW), in line with national PrEP guidelines. Persistence on PrEP was defined as the time to first discontinuation (TFD), either self-reported or estimated as the date when the last dispensed PrEP pill would have been exhausted if taken daily. Categories for discontinuation included participant-reported causes and loss to follow-up (LTFU). TFD was evaluated using survival analysis. Cox proportional hazards models were fitted to examine associations between TFD and sociodemographic and behavioural factors.
resultsOverall, 970 individuals initiated PrEP: 69% MSM, 24% TGW and 6% cSW. Median age was 31 years (IQR 26-36). During follow-up, 447 participants (46%) discontinued PrEP. Persistence declined steadily over time: 91% at 1 month, 81% at 6 months, 72% at 12 months, 58% at 24 months and 43% at 36 months. Main categories for discontinuation were LTFU (44%), user decision or perceived low risk (46% combined) and adverse events (10%). In the multivariable model, younger age, identifying as TGW or cSW, cocaine use in the last month before baseline and the absence of basal/follow-up syphilis or other bacterial sexually transmitted infections were associated with PrEP discontinuation.
conclusionsNearly half of the cohort discontinued PrEP over 3 years, with differences across key populations. These findings highlight the need for differentiated community-tailored PrEP delivery models that address structural and behavioural barriers to improve long-term PrEP engagement among key populations in Argentina and wider Latin America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.